Behavior Genetics

, Volume 25, Issue 6, pp 557–568

Genetic analysis of anxiety-related behaviors and responses to benzodiazepine-related drugs in AXB and BXA recombinant inbred mouse strains

  • Chantal Mathis
  • Paul E. Neumann
  • Howard Gershenfeld
  • Steven M. Paul
  • Jacqueline N. Crawley
Article

DOI: 10.1007/BF02327579

Cite this article as:
Mathis, C., Neumann, P.E., Gershenfeld, H. et al. Behav Genet (1995) 25: 557. doi:10.1007/BF02327579

Abstract

Recombinant inbred (RI) strains derived from the C57BL/6J and A/J mouse strains were used for behavioral studies designed to estimate the number and location of chromosomal loci responsible for anxiety-related behaviors and differential sensitivity to agonists and inverse agonists of the γ-aminobutyric acidA (GABAA)/benzodiazepine receptor complex. The phenotypes of the parental inbred strains and of 28 RI strains were characterized for the number of transitions in the light ⇆ dark exploratory model, anxiolytic response to diazepam, vertical and ambulatory activities in an open field, and sensitivity to the convulsant properties of methyl-β-carboline-3-carboxylate (β-CCM). The strain distribution patterns and estimates of the minimal number of loci obtained for each trait suggest that multiple chromosomal loci contribute to differences in anxiety-related behavioral phenotypes and the behavioral responses to diazepam and β-CCM between C57BL/6J and A/J mice. The best probabilities of linkage were found between the variables characterizing response to diazepam and loci on chromosomes 1 (Xmv-41) and 10 (D10Mit2) and between the sensitivity to the convulsant actions of β-CCM and locusD15Mit5 on chromosome 15.

Key Words

Gene mappinganxietyβ-carbolinerecombinant inbredexploratory activityseizureγ-aminobutyric acidbenzodiazepine

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Chantal Mathis
    • 1
  • Paul E. Neumann
    • 2
  • Howard Gershenfeld
    • 3
  • Steven M. Paul
    • 3
  • Jacqueline N. Crawley
    • 1
  1. 1.Section on Behavioral Neuropharmacology, Experimental Therapeuties Branch, National Institute of Mental HealthNational Institutes of HealthBethesda
  2. 2.Department of Anatomy & Neurobiology and Division of Molecular Pathology & Molecular Genetics, Department of PathologyDalhousie UniversityHalifaxCanada
  3. 3.Section on Molecular Pharmacology, Clinical Neuroscience Branch, National Institute of Mental HealthNational Institutes of HealthBethesda
  4. 4.Laboratoire de PsychophysiologieULP, URA CNRS 1295StrasbourgFrance
  5. 5.Lilly Research Laboratories, Lilly Corporate CenterEli Lilly and Co.Indianapolis